Protocol Ledger

NCT04594707 · Phase III · TERMINATED

A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis

Interventional Phase III clinical trial protocol NCT04594707 sponsored by Roche / Genentech in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-08-30 Enrollment: 117 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04594707
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)117 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04594707
Protocol FieldVerified Registry Value
NCT IdentifierNCT04594707
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment117 participants (ACTUAL)
Registered Start Date2021-08-30
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI